ADVERSE REACTIONS
ZAROXOLYN is usually well tolerated, and most reported adverse reactions have been mild and transient. Many ZAROXOLYN related adverse reactions represent extensions of its expected pharmacologic activity and can be attributed to either its antihypertensive action or its renal/metabolic actions. The following adverse reactions have been reported. Several are single or comparably rare occurrences. Adverse reactions are listed in decreasing order of severity within body systems.
Cardiovascular
Chest pain/discomfort, orthostatic hypotension, excessive volume depletion, hemoconcentration, venous thrombosis, palpitations.
Central And Peripheral Nervous System
Syncope, neuropathy, vertigo, paresthesias, psychotic depression, impotence, dizziness/lightheadedness, drowsiness, fatigue, weakness, restlessness (sometimes resulting in insomnia), headache.
Dermatologic/Hypersensitivity
Toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome, necrotizing angiitis (cutaneous vasculitis), skin necrosis, purpura, petechiae, dermatitis (photosensitivity), urticaria, pruritus, skin rashes.
Gastrointestinal
Hepatitis, intrahepatic cholestatic jaundice, pancreatitis, vomiting, nausea, epigastric distress, diarrhea, constipation, anorexia, abdominal bloating, abdominal pain.
Hematologic
Aplastic/hypoplastic anemia, agranulocytosis, leukopenia, thrombocytopenia.
Metabolic
Hypokalemia, hyponatremia, hyperuricemia, hypochloremia, hypochloremic alkalosis, hyperglycemia, glycosuria, increase in serum urea nitrogen (BUN) or creatinine, hypophosphatemia, hypomagnesemia, hypercalcemia.
Musculoskeletal
Joint pain, acute gouty attacks, muscle cramps or spasm.
Other
Transient blurred vision, chills, dry mouth.
In addition, adverse reactions reported with similar antihypertensive-diuretics, but which have not been reported to date for ZAROXOLYN include: bitter taste, sialadenitis, xanthopsia, respiratory distress (including pneumonitis), and anaphylactic reactions. These reactions should be considered as possible occurrences with clinical usage of ZAROXOLYN.
Whenever adverse reactions are moderate or severe, ZAROXOLYN dosage should be reduced or therapy withdrawn.
|
REPORTS OF SUSPECTED ZAROXOLYN SIDE EFFECTS / ADVERSE REACTIONS
Below is a sample of reports where side effects / adverse reactions may be related to Zaroxolyn. The information is not vetted and should not be considered as verified clinical evidence.
Possible Zaroxolyn side effects / adverse reactions in 76 year old female
Reported by a physician from Israel on 2011-10-18
Patient: 76 year old female
Reactions: Hyponatraemia, Bronchitis
Adverse event resulted in: hospitalization
Suspect drug(s):
Apidra
Dosage: 14 iu
Indication: Type 2 Diabetes Mellitus
Lantus
Dosage: 21 iu
Indication: Type 2 Diabetes Mellitus
Saxagliptin/placebo
Indication: Type 2 Diabetes Mellitus
Start date: 2010-08-12
End date: 2011-03-10
Zaroxolyn
Start date: 2010-12-01
Other drugs received by patient: Calcium Antagonist; Hypertension Agent; Statin; Clopidogrel Bisulfate; Diuretics; Angiotensin Receptor Blocker; Aspirin
Possible Zaroxolyn side effects / adverse reactions in 76 year old female
Reported by a physician from Israel on 2011-12-15
Patient: 76 year old female
Reactions: Confusional State, Hyponatraemia, Bronchitis
Adverse event resulted in: hospitalization
Suspect drug(s):
Apidra
Dosage: 14 iu
Indication: Type 2 Diabetes Mellitus
Lantus
Dosage: 21 iu
Indication: Type 2 Diabetes Mellitus
Saxagliptin/placebo
Indication: Type 2 Diabetes Mellitus
Start date: 2010-08-12
End date: 2011-03-10
Zaroxolyn
Start date: 2010-12-01
Other drugs received by patient: Statin; Enoxaparin Sodium; Prilosec; Calcium Antagonist; Proscar; Bondormin; Aldactone; Aspirin; Diuretics; Clopidogrel Bisulfate; Angiotensin Receptor Blocker; Hypertension Agent; Cadex; Coumadin; Vaben
Possible Zaroxolyn side effects / adverse reactions in 76 year old female
Reported by a physician from Israel on 2011-12-22
Patient: 76 year old female
Reactions: Confusional State, Hyponatraemia, Bronchitis
Adverse event resulted in: hospitalization
Suspect drug(s):
Apidra
Dosage: 14 iu
Indication: Type 2 Diabetes Mellitus
Lantus
Dosage: 21 iu
Indication: Type 2 Diabetes Mellitus
Saxagliptin/placebo
Indication: Type 2 Diabetes Mellitus
Start date: 2010-08-12
End date: 2011-03-10
Zaroxolyn
Start date: 2010-12-01
Other drugs received by patient: Hypertension Agent; Clopidogrel Bisulfate; Bondormin; Calcium Antagonist; Prilosec; Proscar; Cadex; Coumadin; Vaben; Diuretics; Statin; Aldactone; Angiotensin Receptor Blocker; Aspirin; Enoxaparin Sodium
|
